Trials / No Longer Available
No Longer AvailableNCT02376751
An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 8 Months
- Healthy volunteers
- —
Summary
This is an open-label, multicenter expanded access protocol to allow patients with a confirmed diagnosis of Lysosomal Acid Lipase (LAL) Deficiency in the United States (US), access to sebelipase alfa (recombinant lysosomal acid lipase \[rhLAL\]) until commercial product is available. Patients enrolled in the expanded access protocol will receive 1 mg/kg intravenous infusions of sebelipase alfa every other week.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sebelipase alfa |
Timeline
- First posted
- 2015-03-03
- Last updated
- 2016-06-08
Source: ClinicalTrials.gov record NCT02376751. Inclusion in this directory is not an endorsement.